Adam Binder is an Oncology physician affiliated with Thomas Jefferson University. OpenAlex indexes 150 publications with 1,021 citations (h-index 12); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
925 Chestnut St Ste 320a
Philadelphia, PA 19107
Telephone
215-955-8874Registry record last updated 9 Oct 2018.
Clinical trials
- Home Based Daratumumab Administration for Patients With Multiple Myeloma
Sponsor: Thomas Jefferson University
- Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma
Sponsor: Thomas Jefferson University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20259 payments$10,298openpaymentsdata.cms.gov ↗
- Karyopharm Therapeutics Inc.Program year20255 payments
- Janssen Scientific Affairs, LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
21.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.9%Valacyclovir100%Part D≥49 patientsShort-acting sulfonamides1.8%Sulfamethoxazole-Trimethoprim100%Part D≥12 patients+ 1 more class in this area
Nervous system
18.4%Gabapentinoids7.3%Gabapentin59%Pregabalin41%Part D<11 patientsOpioid Agonist6.1%Oxycodone Hcl72%Fentanyl28%Part D<11 patients+ 2 more classes in this area
Cardiovascular
14.7%Loop diuretic4.4%Furosemide100%Part D≥11 patientsCalcium channel blocker3.6%Amlodipine Besylate65%Diltiazem 24hr Er (Cd)35%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Distinguishing Infection- Vs. Non-Infection-Related Febrile Neutropenia in HCT Patients By Machine Learning Analysis of Continuous Body Temperature Data Collected Using a Wearable Sensor
Biology of Blood and Marrow Transplantation
2024 - Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
Frontiers in Immunology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David Whellan, MD
Thomas Jefferson University
Jesse Roman, MD
Thomas Jefferson University
Stephen Silberstein, MD
Thomas Jefferson University
David Cognetti, MD
Thomas Jefferson University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”